{"id":69221,"date":"2026-07-02T14:37:42","date_gmt":"2026-07-02T06:37:42","guid":{"rendered":"https:\/\/flcube.com\/?p=69221"},"modified":"2026-07-02T14:37:43","modified_gmt":"2026-07-02T06:37:43","slug":"ribo-life-science-achieves-first-milestone-in-sirna-collaboration-with-madrigal-for-mash-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69221","title":{"rendered":"Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Ribo Life Science<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6938:HKG\">HKG: 6938<\/a>) announced the achievement of its <strong>first development milestone<\/strong>\u2014<strong>selection of a candidate drug<\/strong>\u2014in its strategic <strong>siRNA collaboration program<\/strong> with <strong>Madrigal Pharmaceuticals<\/strong>, marking significant progress toward advancing cutting-edge RNA therapeutics for liver diseases, with primary focus on <strong>metabolic dysfunction-associated steatohepatitis (MASH)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-collaboration-framework\" class=\"wp-block-heading\">Collaboration Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partnership Date<\/strong><\/td><td>February 2026<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Exclusive global licensing agreement<\/td><\/tr><tr><td><strong>Asset Class<\/strong><\/td><td>Multiple siRNA therapeutic assets<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Metabolic dysfunction-associated steatohepatitis (MASH)<\/td><\/tr><tr><td><strong>Milestone Achieved<\/strong><\/td><td>Candidate drug selection<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Global rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-therapeutic-focus-amp-market-context\" class=\"wp-block-heading\">Therapeutic Focus &amp; Market Context<\/h2>\n\n\n\n<h3 id=\"h-metabolic-dysfunction-associated-steatohepatitis-mash\" class=\"wp-block-heading\">Metabolic Dysfunction-Associated Steatohepatitis (MASH)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Burden:<\/strong> Affects approximately 100 million people globally, representing the progressive form of non-alcoholic fatty liver disease (NAFLD)<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> No approved pharmacotherapies specifically targeting MASH pathogenesis<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Projected to become a multi-billion dollar therapeutic category as diagnostic criteria standardize and awareness increases<\/li>\n\n\n\n<li><strong>Therapeutic Challenge:<\/strong> Requires multi-target approaches addressing inflammation, fibrosis, and metabolic dysregulation simultaneously<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-sirna-technology-advantages\" class=\"wp-block-heading\">siRNA Technology Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Targeting:<\/strong> Enables specific gene silencing with high potency and durability<\/li>\n\n\n\n<li><strong>Liver Tropism:<\/strong> Natural accumulation in hepatocytes makes siRNA ideal for liver-directed therapies<\/li>\n\n\n\n<li><strong>Dosing Regimen:<\/strong> Potential for infrequent subcutaneous administration (quarterly or biannual)<\/li>\n\n\n\n<li><strong>Clinical Validation:<\/strong> Multiple siRNA liver programs have demonstrated safety and efficacy in late-stage development<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ribo Life Science Positioning:<\/strong> Establishes the company as a key player in the global RNA therapeutics landscape through partnership with established biopharmaceutical leader<\/li>\n\n\n\n<li><strong>Madrigal Synergy:<\/strong> Complements Madrigal&#8217;s existing MASH portfolio, potentially creating combination opportunities with their thyroid hormone receptor-\u03b2 (THR-\u03b2) agonist platform<\/li>\n\n\n\n<li><strong>Financial Impact:<\/strong> Milestone achievement likely triggers undisclosed upfront payment and positions the program for subsequent clinical development funding<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Places the collaboration among leading MASH therapeutic approaches, competing with FXR agonists, ACC inhibitors, and other novel mechanisms<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding development milestones and strategic partnerships. Actual results may differ due to risks including preclinical and clinical development outcomes, regulatory approvals, and competitive dynamics in the MASH therapeutic space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070200088_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026070200088_c.\"><\/object><a id=\"wp-block-file--media-1d3a9292-1a32-40f5-ae34-0ced88a3bef8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070200088_c.pdf\">2026070200088_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070200088_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1d3a9292-1a32-40f5-ae34-0ced88a3bef8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ribo Life Science (HKG: 6938) announced the achievement of its first development milestone\u2014selection of a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4524,76,1725,64],"class_list":["post-69221","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-6938","tag-nash","tag-ribo-life-science","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ribo Life Science (HKG: 6938) announced the achievement of its first development milestone\u2014selection of a candidate drug\u2014in its strategic siRNA collaboration program with Madrigal Pharmaceuticals, marking significant progress toward advancing cutting-edge RNA therapeutics for liver diseases, with primary focus on metabolic dysfunction-associated steatohepatitis (MASH).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69221\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Ribo Life Science (HKG: 6938) announced the achievement of its first development milestone\u2014selection of a candidate drug\u2014in its strategic siRNA collaboration program with Madrigal Pharmaceuticals, marking significant progress toward advancing cutting-edge RNA therapeutics for liver diseases, with primary focus on metabolic dysfunction-associated steatohepatitis (MASH).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69221\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-02T06:37:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-02T06:37:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69221#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69221\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics\",\"datePublished\":\"2026-07-02T06:37:42+00:00\",\"dateModified\":\"2026-07-02T06:37:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69221\"},\"wordCount\":332,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 6938\",\"NASH\",\"Ribo Life Science\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69221#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69221\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69221\",\"name\":\"Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-02T06:37:42+00:00\",\"dateModified\":\"2026-07-02T06:37:43+00:00\",\"description\":\"Ribo Life Science (HKG: 6938) announced the achievement of its first development milestone\u2014selection of a candidate drug\u2014in its strategic siRNA collaboration program with Madrigal Pharmaceuticals, marking significant progress toward advancing cutting-edge RNA therapeutics for liver diseases, with primary focus on metabolic dysfunction-associated steatohepatitis (MASH).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69221#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69221\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69221#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics - Insight, China&#039;s Pharmaceutical Industry","description":"Ribo Life Science (HKG: 6938) announced the achievement of its first development milestone\u2014selection of a candidate drug\u2014in its strategic siRNA collaboration program with Madrigal Pharmaceuticals, marking significant progress toward advancing cutting-edge RNA therapeutics for liver diseases, with primary focus on metabolic dysfunction-associated steatohepatitis (MASH).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69221","og_locale":"en_US","og_type":"article","og_title":"Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics","og_description":"Ribo Life Science (HKG: 6938) announced the achievement of its first development milestone\u2014selection of a candidate drug\u2014in its strategic siRNA collaboration program with Madrigal Pharmaceuticals, marking significant progress toward advancing cutting-edge RNA therapeutics for liver diseases, with primary focus on metabolic dysfunction-associated steatohepatitis (MASH).","og_url":"https:\/\/flcube.com\/?p=69221","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-02T06:37:42+00:00","article_modified_time":"2026-07-02T06:37:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69221#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69221"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics","datePublished":"2026-07-02T06:37:42+00:00","dateModified":"2026-07-02T06:37:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69221"},"wordCount":332,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 6938","NASH","Ribo Life Science","RNAi \/ ASO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69221#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69221","url":"https:\/\/flcube.com\/?p=69221","name":"Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-02T06:37:42+00:00","dateModified":"2026-07-02T06:37:43+00:00","description":"Ribo Life Science (HKG: 6938) announced the achievement of its first development milestone\u2014selection of a candidate drug\u2014in its strategic siRNA collaboration program with Madrigal Pharmaceuticals, marking significant progress toward advancing cutting-edge RNA therapeutics for liver diseases, with primary focus on metabolic dysfunction-associated steatohepatitis (MASH).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69221#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69221"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69221#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69221"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69221\/revisions"}],"predecessor-version":[{"id":69223,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69221\/revisions\/69223"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}